E-Mail
IMAGE: After four hours, if the infection is not treated it kills all the cells (line 1); Unformulated tobramycin keeps the cells alive, but it does not eradicate the infection (line. view more
Credit: UniSA
World-first nanotechnology developed by the University of South Australia could change the lives of thousands of people living with cystic fibrosis (CF) as groundbreaking research shows it can improve the effectiveness of the CF antibiotic Tobramycin, increasing its efficacy by up to 100,000-fold.
The new technology uses a biomimetic nanostructured material to augment Tobramycin - the antibiotic prescribed to treat chronic Pseudomonas aeruginosa lung infections in severe cases of CF - eradicating the infection in as little as two doses.
Scientists and government pushing for ways to make mRNA vaccines here
Normal text size
Advertisement
The federal government is working with the biotech industry on ways to establish large-scale mRNA vaccine manufacturing in Australia as a group of senior scientists work on a parallel plan to enable local production of the cutting-edge jabs.
The mRNA coronavirus vaccines from Pfizer and Moderna yielded remarkably strong results in clinical trials and are expected to be much easier to reconfigured to cover new viral variants than more conventional inoculations such as AstraZeneca’s, which is being made in Australia by CSL.
Harry Al-Wassiti (L) and Colin Pouton are working on a COVID-19 vaccine at Monash University.